Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

BioLineRx Ltd

Healthcare US BLRX

3.24USD
0.08(2.53%)

Last update at 2026-06-22T20:00:00Z

Day Range

3.153.37
LowHigh

52 Week Range

0.231.77
LowHigh

Fundamentals

  • Previous Close 3.16
  • Market Cap20.98M
  • Volume11900
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-33.08000M
  • Revenue TTM17.05M
  • Revenue Per Share TTM0.24
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.3

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -24.95100M -27.05400M -30.02100M -25.44600M -22.96200M
Minority interest - - - - -
Net income -18.87200M -28.14400M -30.93200M -26.80600M -18.50700M
Selling general administrative 5.07M 4.27M 3.84M 3.74M 4.41M
Selling and marketing expenses 6.46M 1.00M 0.84M 0.86M 1.36M
Gross profit - - - - 0.00000M
Reconciled depreciation 0.65M 0.70M 0.93M 0.94M 0.55M
Ebit -29.15700M -24.77700M -22.92700M -28.11100M -25.60500M
Ebitda -22.13900M -23.43100M -22.33800M -26.88700M -26.85100M
Depreciation and amortization 7.02M 1.35M 0.59M 1.22M -1.24600M
Non operating income net other - - - - -
Operating income -29.15700M -24.77700M -22.92700M -28.11100M -25.60500M
Other operating expenses 29.16M 24.78M 22.93M 28.11M 25.61M
Interest expense 2.16M 0.98M 1.47M 1.83M 0.02M
Tax provision - - - - -
Interest income 0.69M 0.56M 0.24M 0.78M 0.72M
Net interest income -1.11800M -0.44700M -1.25600M -1.07600M 0.70M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -6.07900M 1.09M 0.91M 1.36M -4.45500M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 29.16M 24.78M 22.93M 28.11M 25.61M
Cost of revenue - - - - 0.00000M
Total other income expense net 4.21M -2.27700M -7.09400M 2.67M 2.64M
Discontinued operations - - - - -
Net income from continuing ops -24.95100M -27.05400M -30.02100M -25.44600M -22.96200M
Net income applicable to common shares - -27.05400M -30.02100M -25.44600M -22.96200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 63.92M 76.38M 81.39M 47.29M 53.57M
Intangible assets 14.85M 21.89M 21.70M 21.71M 21.89M
Earning assets - - - - -
Other current assets 1.53M 41.41M 0.13M 0.15M 0.11M
Total liab 50.70M 25.54M 13.30M 25.26M 20.19M
Total stockholder equity 13.22M 50.84M 68.09M 22.03M 33.38M
Deferred long term liab - - - - -
Other current liab 3.35M 1.74M 1.23M 1.44M 0.00700M
Common stock 31.36M 27.10M 21.07M 9.87M 4.69M
Capital stock 31.36M 27.10M 21.07M 9.87M 4.69M
Retained earnings -390.60600M -329.99200M -305.04100M -277.98700M -247.96600M
Other liab - - 1.86M 10.22M 0.66M
Good will - - - - -
Other assets 0.00000M - - - -
Cash 4.25M 10.59M 12.99M 16.83M 5.30M
Cash and equivalents - - - - -
Total current liabilities 30.85M 10.68M 9.72M 10.64M 11.97M
Current deferred revenue 12.96M - - 0.00300M 1.27M
Net debt 7.34M 1.74M -8.33900M -9.14700M 5.16M
Short term debt 3.67M 1.97M 2.92M 3.28M 2.89M
Short long term debt 3.15M 1.54M 2.76M 3.09M 2.69M
Short long term debt total 11.59M 12.32M 4.65M 7.68M 10.46M
Other stockholder equity 355.48M 340.38M 340.32M 279.24M 265.94M
Property plant equipment - - 2.28M 2.70M 3.47M
Total current assets 47.18M 52.00M 57.40M 22.88M 28.21M
Long term investments - - - - -
Net tangible assets - - 46.38M 0.32M 11.49M
Short term investments 38.74M 40.49M 44.15M 5.76M 22.19M
Net receivables 0.71M 0.72M 0.14M 0.14M 0.61M
Long term debt 6.63M 8.63M - 2.74M 5.80M
Inventory 1.95M -41.21600M - - -
Accounts payable 10.87M 6.97M 5.57M 5.92M 7.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 16.99M 13.35M 11.74M 10.91M 10.72M
Additional paid in capital - - - - -
Common stock total equity - - - 9.87M 4.69M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M - - 21.40M 25.36M
Deferred long term asset charges - - - - -
Non current assets total 16.74M 24.38M 23.99M 24.41M 25.36M
Capital lease obligations 1.82M 2.16M 1.89M 1.85M 1.96M
Long term debt total - - - - 7.56M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 4.01M -38.12700M 16.67M 5.26M 9.55M
Change to liabilities 0.00000M -0.56400M -1.71600M 3.22M -0.77300M
Total cashflows from investing activities - -38.22400M 16.67M 5.26M 9.55M
Net borrowings - -3.57200M -3.35700M -1.10400M 9.22M
Total cash from financing activities 20.44M 57.75M 17.87M 19.19M 13.10M
Change to operating activities - 0.02M 0.43M 1.11M -0.93400M
Net income -24.95100M -27.05400M -30.02100M -25.44600M -22.96200M
Change in cash -2.40300M -3.84100M 11.53M 1.89M -1.70600M
Begin period cash flow 12.99M 16.83M 5.30M 3.40M 5.11M
End period cash flow 10.59M 12.99M 16.83M 5.30M 3.40M
Total cash from operating activities -26.24000M -23.57300M -23.20600M -22.66600M -24.19200M
Issuance of capital stock 14.36M 50.41M 21.21M 20.30M 3.83M
Depreciation 0.65M 0.70M 0.93M 0.94M 0.55M
Other cashflows from investing activities - - - 5.33M 19.77M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - 20.30M 3.88M
Other cashflows from financing activities 9.13M 10.91M 0.00800M 0.00100M 9.68M
Change to netincome - 3.32M 6.58M -2.95700M -0.07300M
Capital expenditures 0.32M 0.10M 0.10M 0.07M 10.22M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.24M -0.54000M -1.28800M 4.32M -1.70700M
Stock based compensation 2.25M 1.50M 1.27M 1.76M 2.53M
Other non cash items -5.42600M 0.04M 0.24M -0.07200M -2.59400M
Free cash flow -26.55600M -23.67000M -23.20600M -22.73900M -34.40800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BLRX
BioLineRx Ltd		 0.08 2.53% 3.24 - - 1.23 2.47 1.25 -0.6709
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd

Modi?in Technology Park, Hevel Modi'in, Israel, 7177871

Key Executives

Name Title Year Born
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA Chief Exec. Officer 1960
Ms. Mali Zeevi CPA, CPA Chief Financial Officer 1976
Dr. Ella Sorani Chief Devel. Officer 1968
Mr. John Lacey Head of Corp. Communications & Investor Relations NA
Advocate Norman Kotler Internal Enforcement Officer, Gen. Counsel and Corp. Sec. 1952
Ms. Liron Shemesh-Darvish M.B.A., Ph.D. Sr. Director & Head of Preclinical Devel. NA
Ms. Jael Birenberg M.Sc. Sr. Director & Head of RA, QA and PhV NA
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. Head of BD & Strategic Advisor NA
Ms. Holly W. May M.B.A. Pres of BioLineRx USA NA
Mr. Raziel Fried Treasurer & Budgetary Control Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions